San Diego-based Viking Therapeutics marked by itself as a significant competitor during the weight loss drug industry in February right after revealing promising data from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March the company